Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe-Reference-Cited by-同舟云学术

Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe

Published:2019-01 Issue:1 Volume:19 Page:97-104
ISSN:1424-3903
Container-title:Pancreatology
language:en
Short-container-title:Pancreatology

Author:

Javed Muhammad Ahsan,Beyer Georg^ORCID,Le Nha,Vinci Alessio,Wong Helen,Palmer Daniel,Morgan Robert D.,Lamarca Angela,Hubner Richard A.,Valle Juan W.^ORCID,Alam Salma,Chowdhury Sumsur,Ma Yuk Ting,Archibugi Livia,Capurso Gabriele^ORCID,Maisonneuve Patrick,Neesse Albrecht,Sund Malin^ORCID,Schober Marvin,Krug Sebastian

Funder

Pancreatic Cancer Research Fund

Spanish Society of Medical Oncology

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology,Endocrinology, Diabetes and Metabolism

Reference32 articles.

1. Cancer statistics, 2013;Siegel;Ca - Cancer J Clin,2013

2. Pancreatic cancer: epidemiology and risk factors;Krejs;Dig Dis Basel Switz,2010

3. Pancreatic cancer;Vincent;Lancet Lond Engl,2011

4. New advances in the treatment of metastatic pancreatic cancer;Schober;Digestion,2015

5. Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030;Quante;Cancer Med,2016

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gemcitabine–Lipid Conjugate and ONC201 Combination Therapy Effectively Treats Orthotopic Pancreatic Tumor-Bearing Mice;ACS Applied Materials & Interfaces;2024-05-30

2. An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic cancer;Cell Reports Medicine;2024-02

3. Real‑world treatment outcomes among patients with metastatic pancreatic cancer in Japan: The Tokushukai real‑world data project;Molecular and Clinical Oncology;2023-10-25

4. Real-Life Results of Palliative Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma;Cancers;2023-07-05

5. Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer;Cancers;2023-01-05